Company news
Connect Biopharma Holdings Limited news in 2025
Connect Biopharma Holdings Limited's news releases, calls and decks from 2025, newest first.
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
November 24, 2025
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
November 14, 2025
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
November 11, 2025
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3
October 30, 2025
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
September 29, 2025
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
September 3, 2025
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
September 2, 2025
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
August 27, 2025
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
August 14, 2025
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
July 21, 2025
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
July 20, 2025
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
July 18, 2025
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 16, 2025
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
July 9, 2025
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
June 13, 2025
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
June 2, 2025
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
May 28, 2025
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
May 20, 2025
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
May 14, 2025
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
May 12, 2025
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
April 23, 2025
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
March 31, 2025
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
March 30, 2025
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
March 30, 2025
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
March 27, 2025